Use of Baloxavir Marboxil Post-Exposure Prophylaxis to Halt an Influenza A(H3) Outbreak in a College Sports Team, November 2024
Baloxavir marboxil is approved for influenza treatment and post-exposure prophylaxis (PEP). There are limited real-world examples of its use in influenza outbreaks. Here, we describe the use of baloxavir marboxil as PEP to halt an influenza outbreak among a college sports team during the 2024-2025 influenza season.
Authors
- Annabelle de St. Maurice (ORCID: https://orcid.org/0000-0001-7368-7403)
- Elizabeth Traub
- Sharon Balter
- Noah Kojima (ORCID: https://orcid.org/0000-0002-3667-9719)
- Nicole M. Green (ORCID: https://orcid.org/0000-0001-5427-0944)
- Allison Joyce (ORCID: https://orcid.org/0000-0001-6127-4724)
- Amy Marutani
- Erika Yanez
- Jan King
- Sheree R Poitier
- Earl J Erezo
Institutions
- Los Angeles County Department of Public Health (US)
- Los Angeles County Department of Health Services (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1093/cid/ciaf148
- Primary Topic
- Cardiovascular Effects of Exercise
- Type
- article
- Field-Weighted Citation Impact
- 0.00